Stability of Erythropoietin repackaging in polypropylene syringes for clinical use
Discussion We demonstrate that repackaging of EPO does not alter its concentration if compared to the original product (Eprex®). This is true both for repackaging procedures as for the stability in polypropylene tubes. The expiration date of r-EPO can be extended from 1 to 4 months after repackaging, in accordance to pharmacopeia rules. (Source: Saudi Pharmaceutical Journal)
Source: Saudi Pharmaceutical Journal - January 16, 2016 Category: Drugs & Pharmacology Source Type: research
382P * Synergy between epoetin alfa biosimilar and IV iron in chemotherapy-induced anemia
(Source: Annals of Oncology)
Source: Annals of Oncology - December 19, 2015 Category: Cancer & Oncology Authors: Scotte, F., Laribi, K., Ray-Coquard, I., Kasdaghli, E., Gisselbrecht, C., Leutenegger, E., Spaeth, D., Albrand, H. Tags: Supportive and palliative care Source Type: research
373PD * Real-life efficacy of an epoetin alfa biosimilar in chemotherapy-induced anemia
(Source: Annals of Oncology)
Source: Annals of Oncology - December 19, 2015 Category: Cancer & Oncology Authors: Scotte, F., Laribi, K., Gisselbrecht, C., Spaeth, D., Kasdaghli, E., Leutenegger, E., Ray-Coquard, I., Albrand, H. Tags: Supportive and palliative care Source Type: research
Impact of Hematopoietic Growth Factors on Blood Transfusion Needs, Incidence of Neutropenia, and Overall Survival Among Elderly Advanced Ovarian Cancer Patients Treated With Chemotherapy
Conclusions: Erythropoietin-stimulating agents were effective in reducing blood transfusion need. Granulocyte colony-stimulating factors were effective in lowering neutropenia incidence and also were associated with improved survival in elderly ovarian cancer patients. Findings are consistent with clinical trials and clinical guidelines. (Source: International Journal of Gynecological Cancer)
Source: International Journal of Gynecological Cancer - December 15, 2015 Category: Cancer & Oncology Tags: Ovarian Cancer Source Type: research
Reduction of costs for anemia-management drugs associated with the use of ferric citrate.
CONCLUSION: It is likely that US health care costs for anemia-management drugs associated with ESRD among HD patients can be reduced by using ferric citrate as a phosphate binder.
PMID: 24899820 [PubMed] (Source: International Journal of Nephrology and Renovascular Disease)
Source: International Journal of Nephrology and Renovascular Disease - November 28, 2015 Category: Urology & Nephrology Tags: Int J Nephrol Renovasc Dis Source Type: research
Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability.
CONCLUSION: In patients on hemodialysis receiving ESAs, conversion from epoetin alfa to darbepoetin alfa was associated with an approximate and persistent reduction of 65% of the required dose. To maintain Hb stability, a conversion rate of 300:1 seems to be appropriate for most patients receiving low doses of epoetin alfa (≤200 IU/kg/week), while 350:1 would be better for patients receiving higher doses.
PMID: 25336984 [PubMed] (Source: International Journal of Nephrology and Renovascular Disease)
Source: International Journal of Nephrology and Renovascular Disease - November 28, 2015 Category: Urology & Nephrology Tags: Int J Nephrol Renovasc Dis Source Type: research
Methodological Concerns About a Systematic Review and Meta-analysis of the Mortality Risk of Darbepoetin Alfa Versus Epoetin Alfa
Publication date: December 2015 Source:American Journal of Kidney Diseases, Volume 66, Issue 6 Author(s): Hiraku Tsujimoto, Yuki Kataoka, Yasushi Tsujimoto (Source: American Journal of Kidney Diseases)
Source: American Journal of Kidney Diseases - November 22, 2015 Category: Urology & Nephrology Source Type: research
Efficiency of erythropoiesis-stimulating agents (ESA) in the treatment of chemotherapy-induced anemia in patients with lung cancer (LC)
In this study epoetin alfa was better in terms of efficiency than epoetin beta and darbepoetin. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Tiotiu, A., Clerc-Urmes, I., Martinet, Y. Tags: 11.1 Lung Cancer Source Type: research
Early response to erythropoiesis-stimulating agents in non-dialysis chronic kidney disease patients
Conclusions
The study results suggest that TSAT is the best predictor of the initial 12-week responsiveness to ESA, irrespective of the type. Variables not investigated in this study also affect responsiveness to ESA in Japanese pre-dialysis CKD patients. (Source: Clinical and Experimental Nephrology)
Source: Clinical and Experimental Nephrology - October 28, 2015 Category: Urology & Nephrology Source Type: research
N29 * Biosimilar epoetin alfa in the management of chemotherapy-induced aneamia: results from ANEMONE observational study
(Source: Annals of Oncology)
Source: Annals of Oncology - October 26, 2015 Category: Cancer & Oncology Authors: Scelzi, E., Bernardi, D., Bonciarelli, G., Salesi, N., Frassoldati, A., Maisano, R., Tagliaferri, P., Gamucci, T., Mencoboni, M., Raggi, T., Rosti, G. Tags: Session N. Simultaneous care Source Type: research
Trends in Anemia Management in Hemodialysis Patients with Cancer.
CONCLUSIONS: Despite safety concerns about ESAs in both the ESRD and cancer populations, the proportion of hemodialysis patients with cancer who used ESAs between 2000 and 2011 remained extremely high. EPO dose and hemoglobin levels increased and then decreased. Iron use, iron dose, and transfusions increased substantially. Future research examining the risk-benefit profile of different anemia management strategies in the dialysis population with cancer is needed.
PMID: 26439712 [PubMed - as supplied by publisher] (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - October 7, 2015 Category: Urology & Nephrology Authors: Butler AM, Kshirsagar AV, Olshan AF, Nielsen ME, Wheeler SB, Brookhart MA Tags: Am J Nephrol Source Type: research
Trends in Anemia Management in Hemodialysis Patients with Cancer
Conclusions: Despite safety concerns about ESAs in both the ESRD and cancer populations, the proportion of hemodialysis patients with cancer who used ESAs between 2000 and 2011 remained extremely high. EPO dose and hemoglobin levels increased and then decreased. Iron use, iron dose, and transfusions increased substantially. Future research examining the risk-benefit profile of different anemia management strategies in the dialysis population with cancer is needed.Am J Nephrol 2015;42:206-215 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - October 6, 2015 Category: Neurology Source Type: research
Pharmacokinetic and Pharmacodynamic Comparison of Two Recombinant Human Erythropoietin Formulations, PDA10 and Eprex, in Healthy Korean Male Volunteers: A Randomized, Double-Blinded, Single-Dose, Two-Period Crossover Study
Conclusion
PDA10 and Eprex met the regulatory criteria for bioequivalence with respect to their pharmacokinetic profiles and pharmacodynamic actions. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - September 14, 2015 Category: Drugs & Pharmacology Source Type: research
Pre-Procedural Anemia Management Decreases Transfusion Rates in Patients Undergoing Transcatheter Aortic Valve Implantation
Conclusions Pre-procedural anemia management was successful in improving hemoglobin levels in anemic patients and in decreasing transfusion rates in TAVI. Teaser We assessed the impact of a pre-operative anemia management in treating anemia and preventing blood transfusion in TAVI. Between 2012 and 2014, 239 patients underwent TAVI. Since March 2013, anemic TAVI candidates were referred to the blood conservation clinic and treated with intravenous/oral iron and/or subcutaneous epoetin alfa. Patients who underwent blood conservation had a significant increase in hemoglobin levels. Implementation of the BCC was associated w...
Source: Canadian Journal of Cardiology - August 29, 2015 Category: Cardiology Source Type: research
Identification of recombinant human EPO variants in greyhound plasma and urine by ELISA, LC‐MS/MS and western blotting: a comparative study
The recombinant human erythropoietins epoetin alfa (Eprex®), darbepoetin (Aranesp®) and methoxy polyethylene glycol‐epoetin beta (Mircera®) were administered to greyhounds for 7, 10 and 14 days respectively. Blood and urine samples were collected and analysed for erythropoietin by ELISA, LC‐MS/MS and western blotting. Limits of confirmation in plasma for western blotting and LC‐MS/MS methods ranged from a low of 2.5mIU/mL, and closely matched the sensitivity of ELISA screening. Copyright © 2015 John Wiley & Sons, Ltd.
Epoetin alfa, darbopoietin and pegylated Epoetin beta were administered to greyhounds and r...
Source: Drug Testing and Analysis - August 1, 2015 Category: Drugs & Pharmacology Authors: Mark Timms, Rohan Steel, John Vine Tags: Research article Source Type: research
